Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

@article{Edan2011MitoxantronePT,
  title={Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.},
  author={Gilles Edan and Giancarlo Comi and Emmanuelle Le Page and Emmanuelle Leray and Maria Assunta Rocca and Massimo Filippi},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={2011},
  volume={82 12},
  pages={1344-50}
}
OBJECTIVES The long-term impact of interferon-beta-1b (IFN) might be improved by short-term immunosuppression with mitoxantrone (MITOX) in aggressive relapsing-remitting multiple sclerosis (ARMS) patients. METHODS In this 3-year clinical and MRI study, 109 ARMS patients (two or more relapses in the previous 12 months and one or more gadolinium (Gd)-enhancing MRI lesion) were randomised into two groups: 54 patients received MITOX monthly (12 mg/m(2); maximum 20 mg) combined with 1 g of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 24 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Evidence for a two - stage disability progression in multiple sclerosis

  • AJ Coles, DA Compston, KW Selmaj
  • Brain
  • 2010

Alemtuzumab vs Interferonbeta - 1 a in early multiple sclerosis

  • EJ Fox
  • N Engl J Med
  • 2008

Similar Papers

Loading similar papers…